Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion type Assertion NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_head.
- NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion wasGeneratedBy ECO_0000203 NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_provenance.
- NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion wasDerivedFrom befree-2016 NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_provenance.
- NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion SIO_000772 8219189 NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_provenance.
- NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion evidence source_evidence_literature NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_provenance.
- NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_assertion description "[Thus, confirmation of remission duration or survival benefit, if any, of r alpha 2bIFN therapy in Ph-positive chronic-phase CML must await the outcome of randomized trials comparing IFN with conventional agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1335971.RAEl7v8bMTtMe7ZqdwysLjEBbAnxmJU_-wqZddZ1FLyX4130_provenance.